Lilly(Eli) & Co

NYSE:LLY   3:59:59 PM EDT
-5.55 (-2.22%)
: $243.66 -0.46 (-0.19%)

FDA Expands Authorization Of Two Monoclonal Antibodies For Treatment Of Covid-19 To Younger Pediatric Patients, Including Newborns

Published: 12/03/2021 19:42 GMT
Lilly(Eli) & Co (LLY) - :fda Expands Authorization of Two Monoclonal Antibodies for Treatment and Post-exposure Prevention of Covid-19 to Younger Pediatric Patients, Including Newborns.
FDA Says Eua for Bamlanivimab and Etesevimab Was Issued to Eli Lilly and Co.
FDA - Revised Eua of Bamlanivimab & Etesevimab to Authorize Them Together for Treatment of Covid-19 in Younger Pediatric Patients, Including Newborns.
FDA Says Children Under One Year of Age Who Are Exposed to Virus That Causes Covid-19 May Be at Particularly High Risk for Severe Covid-19.
FDA - Also Authorizes Bamlanivimab & Etesevimab for Post-exposure Prophylaxis for Prevention of Covid-19 in All Pediatric Patients, Including Newborns.